FDA advisory committee
Coverage of FDA advisory committee in the Nexus archive.
- 'We Should Follow That Signal': What We Heard This Week
An FDA advisory committee supported RP1 (vusolimogene oderparepvec), a twice-administered treatment, following a statement by John Carrino of Weill Cornell Medicine emphasizing the importance of following observed signals in the data.
- FDA considers widening access to popular peptides
The FDA advisory committee is considering lifting a ban to expand access to seven popular peptides. Wellness influencers and Health Secretary Robert F. Kennedy Jr. have shown support for these peptides, which were discussed in a New Yorker article by Dr. Dhruv Khullar.
- FDA Panel Narrowly Backs Lifting Restrictions on Peptides Backed by RFK Jr.
An FDA advisory committee voted to remove compounding restrictions on peptides BPC-157 and KPV, despite limited evidence of their safety or effectiveness for medical use. The decision was backed by RFK Jr., who promotes these peptides as wellness products.
- FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list
An FDA advisory committee voted to add the popular peptide BPC-157 to a drug compounding list. The decision was made on Thursday, as stated in the article.